Form 4: Summit Therapeutics CEO's Spouse Receives Stock Options

Mahkam Zanganeh's spouse received 11,232 stock options in Summit Therapeutics Inc. in lieu of $98,400 in director retainer fees.

Summary

• Mahkam Zanganeh, Co-Chief Executive Officer, Director, and 10% Owner of Summit Therapeutics Inc. (SMMT), reported an acquisition of derivative securities.
• The transaction involved 11,232 stock options granted to Zanganeh's spouse on January 2, 2026.
• These options were issued under the issuer's Director Retainer Option Election Plan, replacing $98,400 in retainer fees.
• Each option has an exercise price of $17.52 and represents the right to buy one share of common stock.
• The options vest in four quarterly installments on March 31, June 30, September 30, and December 31, contingent on the spouse remaining a non-salaried director.
• The options expire on January 2, 2036.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event involving stock options in lieu of cash, which is generally neutral but can be seen as a positive for cash conservation and alignment of interests. No significant positive or negative operational news is disclosed.

Positives

• The company is utilizing its Director Retainer Option Election Plan, allowing directors to elect equity compensation, which can align their interests with shareholders.
• The grant of options in lieu of cash retainer fees conserves cash for the company.

Risks

• The value of the options is contingent on the future stock price performance of Summit Therapeutics Inc. If the stock price does not exceed the exercise price of $17.52, the options may expire worthless.
• The vesting schedule requires the reporting person's spouse to remain a non-salaried director, introducing a retention risk if the spouse departs.

Future Outlook

The vesting schedule of the options, tied to the spouse remaining a non-salaried director, indicates an expectation of continued service and alignment of interests over the vesting period.

Management Comments

• The reporting person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or any other purpose.

Industry Context

The use of equity compensation, such as stock options, for directors and executives is a common practice in the biotechnology and pharmaceutical industry, aiming to align long-term incentives with shareholder value creation. This particular grant reflects a standard compensation mechanism for non-salaried directors.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a widely accepted practice across various industries, including biotech, to incentivize long-term performance and retention. Companies like Biogen Inc. (BIIB) and Gilead Sciences, Inc. (GILD) frequently use similar equity-based compensation plans for their non-employee directors.
• The specific ratio of options granted to the cash value forgone ($98,400 for 11,232 options, implying an $8.76 per option value) would typically be determined by a compensation committee based on factors such as the company's stock volatility, expected option life, and prevailing market rates for director compensation, often benchmarked against peer groups.
• The vesting schedule, with quarterly installments over a year, is a common approach to ensure continued service and commitment from directors, similar to practices observed at companies like Amgen Inc. (AMGN) for their non-executive board members.

Related Party Transactions

• The stock options were granted to the spouse of Mahkam Zanganeh, who is the Co-Chief Executive Officer, Director, and a 10% Owner of Summit Therapeutics Inc.
• This transaction is considered a related party transaction as it involves a close family member of a key executive and director.

Stakeholder Impact

• Shareholders: The grant of options in lieu of cash conserves company cash, which could be seen as beneficial. It also aims to align the interests of the director's spouse with long-term shareholder value through equity ownership. However, it also represents potential future dilution if options are exercised.
• Creditors: Cash conservation from using equity compensation instead of cash retainer fees could be marginally positive for the company's liquidity position.

Next Steps

• The options will vest in four quarterly installments on March 31, June 30, September 30, and December 31, subject to the spouse remaining a non-salaried director.
• The options can be exercised at any time after vesting until their expiration date of January 2, 2036.

Key Dates

Recommendation

This Form 4 filing details a routine compensation event where a director's spouse received stock options in lieu of cash retainer fees. While it demonstrates the company's use of equity compensation to align interests and conserve cash, it does not provide new material information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transaction is an expected part of executive and director compensation practices.

Keywords

Summit Therapeutics, SMMT, SEC Form 4, Stock Options, Insider Trading, Executive Compensation, Director Compensation, Equity Compensation, Mahkam Zanganeh